R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Jun

Today In Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer

Preclinical Research Shows Interferon May Attenuate Neutrophil Response to Cancer Immunotherapy

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia

Relapsed or Refractory Multiple Myeloma Talquetamab Daratumumab

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer